Back
ESC2025 Premium Access

Empagliflozin preserves hemodynamics and left ventricular function in nephrectomized rats after ischemia-reperfusion injury: a potential direct cardioprotective effect of SGLT2 inhibitor

Session: Innovative therapeutic strategies to combat ischaemia-reperfusion injury and cardiac dysfunction
Topic: Drugs, Drug Targets
Speaker: Doctor K. Akiyoshi (Kasukabe, JP)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Kei Akiyoshi

Kasukabe Chuo General Hospital, Kasukabe (Japan)
0 follower

6 more presentations in this session

PPAR alpha-driven CISD2 upregulation by hesperetin protects against myocardial ischemia/reperfusion injury

Speaker: Professor C. Yeh (Tao-Yuan, TW)

Access
Abstract
Slides
Video
Like
Thumbnail

Organic polydopamine nanoparticles ameliorate endothelial ischemia-reperfusion injury, increasing antioxidant defense and reducing inflammatory response

Speaker: Doctor S. Babboni (Pisa, IT)

Access
Abstract
Slides
Video
Like
Thumbnail

Activation of AMPK via inhibition of PAR2 limits myocardial ischemia-reperfusion injury

Speaker: Doctor L. Li (Winnipeg, CA)

Access
Abstract
Slides
Video
Like
Thumbnail

Novel first-in-class drug candidate protects from ischemia-reperfusion injury by targeting the SERCA2 complex

Speaker: Mrs A. Calejo (Oslo, NO)

Access
Abstract
Slides
Video
Like
Thumbnail

Mitochondria-targeted Hydrogen Sulfide exerts protective effects and maintains mitochondria homeostasis against ischemia reperfusion injury in heart transplantation via the mitofusion-1 pathway

Speaker: Doctor C. Zhu (Changchun, CN)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Innovative therapeutic strategies to combat ischaemia-reperfusion injury and cardiac dysfunction

Speakers: Doctor K. Akiyoshi, Professor C. Yeh, Doctor S. Babboni, Doctor L. Li, Mrs A. Calejo...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources